Characterization of Demographics, Drug Latency, and Mortality of Severe Cutaneous Adverse Reactions in an FDA Pharmacovigilance Database

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.